The antiviral is just about positive in a moderate Covid-19 study, but paradoxically only as a limited regimen.
As three Asco presentations confirm the Her2-targeting agent's potency, Daiichi Sankyo and Astrazeneca lay out an ambitious development programme.
One trial of Pfizer’s drug in early breast cancer has been stopped, and expectations dim for another.
In anti-BCMA therapy Johnson & Johnson looks to have upstaged Bristol Myers Squibb again, and both companies have backups.
The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?
The Merck KGaA/Pfizer drug is said to have cured 52% of women with a rare gynaecological cancer, one of whom subsequently gave birth.
With an 83% reduction in the risk of disease recurrence in early-stage lung cancer, Astrazeneca’s Tagrisso takes the top spot at Asco.
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
The green light comes two months early, revealing data that were being held back for Asco, but what does Yervoy bring to the table?